 "Dr Reddys Lab hits three-month high")
Dr Reddy’s Laboratories have moved higher to three-months high of Rs 3,307, up 2% on the BSE in on otherwise weak market, after the company announced new strategic deal with Gland Pharma in the US market.
The pharmaceutical company said on Wednesday after market hours that it has entered into a strategic collaboration with Hyderabad-based Gland Pharma to market and distributes a diverse portfolio of eight injectable Abbreviated New Drug Applications (ANDAs), or alternatively called as generic drug approvals.
“The portfolio is a mix of filed ANDAs and pending approval by the US Food and Drug Administration (USFDA) and ANDAs that will be filed imminently, and comprised of generic injectables administered in hospitals and clinics in the US, according to a statement issued by the company,” Dr Reddys Lab said in a press release.
The combined sale of branded and generic versions of the products in the US is approximately $1 billion for the most recent twelve months ending in August, 2016, it said citing the IMS Health data, it added.
In past three-trading sessions, post July-September (Q2FY17) results, the stock outperformed the market by gaining 7% as compared to 1.62% decline in the S&P BSE Sensex.
The pharmaceutical company said on Wednesday after market hours that it has entered into a strategic collaboration with Hyderabad-based Gland Pharma to market and distributes a diverse portfolio of eight injectable Abbreviated New Drug Applications (ANDAs), or alternatively called as generic drug approvals.
“The portfolio is a mix of filed ANDAs and pending approval by the US Food and Drug Administration (USFDA) and ANDAs that will be filed imminently, and comprised of generic injectables administered in hospitals and clinics in the US, according to a statement issued by the company,” Dr Reddys Lab said in a press release.
The combined sale of branded and generic versions of the products in the US is approximately $1 billion for the most recent twelve months ending in August, 2016, it said citing the IMS Health data, it added.
In past three-trading sessions, post July-September (Q2FY17) results, the stock outperformed the market by gaining 7% as compared to 1.62% decline in the S&P BSE Sensex.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%